dr. A.M.E. (Annemiek) Walenkamp

Medical Oncologist (MD)

dr. A.M.E. (Annemiek) Walenkamp
E-mail:
a.walenkamp umcg.nl

Research

  1. 2019
  2. French, P. J., Eoli, M., Sepulveda, J. M., de Heer, I., Kros, J. M., Walenkamp, A., ... van den Bent, M. (2019). Defining EGFR amplification status for clinical trial inclusion. Neuro-Oncology, 21(10), 1263-1272. https://doi.org/10.1093/neuonc/noz096
  3. Lassman, A. B., Aldape, K. D., Ansell, P. J., Bain, E., Curran, W. J., Eoli, M., ... van den Bent, M. J. (2019). Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. JOURNAL OF NEURO-ONCOLOGY, 144(1), 205-210. https://doi.org/10.1007/s11060-019-03222-y
  4. 2018
  5. Salazar, R., Garcia-Carbonero, R., Libutti, S. K., Hendifar, A. E., Custodio, A., Guimbaud, R., ... Yao, J. C. (2018). Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naive Advanced Pancreatic Neuroendocrine Tumors. The Oncologist, 23(7), 766-e90. https://doi.org/10.1634/theoncologist.2017-0144
  6. 2017
  7. van Linde, M. E., Brahm, C. G., Hamer, P. C. D. W., Reijneveld, J. C., Bruynzeel, A. M. E., Vandertop, W. P., ... Verheul, H. M. W. (2017). Treatment outcome of patients with recurrent glioblastoma multiforme: A retrospective multicenter analysis. JOURNAL OF NEURO-ONCOLOGY, 135(1), 183-192. https://doi.org/10.1007/s11060-017-2564-z
  8. 2016
  9. Erdem-Eraslan, L., van den Bent, M. J., Hoogstrate, Y., Naz-Khan, H., Stubbs, A., van der Spek, P., ... French, P. J. (2016). Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. Cancer Research, 76(3), 525-534. https://doi.org/10.1158/0008-5472.CAN-15-0776
  10. 2015
  11. Dirven, L., van den Bent, M. J., Bottomley, A., van der Meer, N., van der Holt, B., Vos, M. J., ... Dutch Neuro-Oncology Grp LWNO (2015). The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. European Journal of Cancer, 51(10), 1321-1330. https://doi.org/10.1016/j.ejca.2015.03.025
  12. Boer, J. C., van Marion, D. M. S., Vareecal Joseph, J., Kliphuis, N. M., Timmer-Bosscha, H., van Strijp, J. A. G., ... Walenkamp, A. M. E. (2015). Microenvironment involved in FPR1 expression by human glioblastomas. JOURNAL OF NEURO-ONCOLOGY, 123(1), 53-63. https://doi.org/10.1007/s11060-015-1777-2
  13. 2014
  14. Walenkamp, A., Crespo, G., Fierro Maya, F., Fossmark, R., Igaz, P., Rinke, A., ... Meyer, T. (2014). Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. Endocrine-Related cancer, 21(6), R445-R460. https://doi.org/10.1530/ERC-14-0106
Previous 1 2 Next

ID: 393545